Hepatitis C

Lore & Background

Hepatitis C is caused by the hepatitis C virus (HCV), a small, enveloped, single-stranded, positive-sense RNA virus. It is a member of the genus Orthohepacivirus in the family Hepacivirus. There are seven major genotypes of HCV, with genotype 1 being most common in the United States, South America, and Europe. The virus is spread primarily by blood-to-blood contact associated with injection drug use, poorly sterilized medical equipment, needlestick injuries in healthcare, and transfusions. In regions where blood screening has been implemented, the risk of contracting HCV from a transfusion has dropped substantially to less than one per two million. It may also be spread from an infected mother to her baby during birth, but not through breast milk, food, water, or casual contact.

Reader's Guide

Hepatitis C is significant as a leading cause of chronic liver disease, cirrhosis, and liver cancer worldwide. During the initial infection period, people often have mild or no symptoms; early symptoms can include fever, dark urine, abdominal pain, and jaundice. The virus persists in the liver, becoming chronic, in about 70% of those initially infected. Over many years, chronic infection often leads to liver disease and occasionally cirrhosis, and in some cases, serious complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach. Diagnosis is by blood testing to look for either antibodies to the virus or viral RNA. There is no vaccine against hepatitis C. Prevention includes harm reduction efforts among people who inject drugs, testing donated blood, and treatment of people with chronic infection. Chronic infection can be cured more than 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Earlier treatments like peginterferon and ribavirin were successful in less than 50% of cases and caused greater side effects. While access to newer treatments was expensive, by 2022 prices had dropped dramatically in many countries due to the introduction of generic versions of medicines. Those who develop cirrhosis or liver cancer may require a liver transplant; hepatitis C is one of the leading reasons for liver transplantation, though the virus usually recurs after transplantation.

Did You Know?

• Hepatitis C infects only humans and chimpanzees.
• The existence of hepatitis C was suggested in the 1970s and proven in 1989.
• Chronic infection can be cured more than 95% of the time with antiviral medications such as sofosbuvir or simeprevir.
• In the United States, screening for HCV infection is recommended in all adults age 18 to 79 years old.

The Silent Decades – From Acute Infection to Chronic Damage

When hepatitis C first takes hold, the body often gives little warning. Roughly 20% of newly infected individuals develop acute symptoms between four and twelve weeks after exposure, though the window can stretch to six months. When symptoms appear, they tend to be vague—fatigue, nausea, low-grade fever, muscle aches, diminished appetite, and in about a quarter of cases, jaundice. Acute liver failure is exceedingly rare. In 10 to 50% of cases, the immune system clears the virus spontaneously, a resolution seen more often in younger people and women. For the remaining 70%, the virus establishes a chronic presence in the liver, defined by detectable replication lasting at least six months. The danger lies in silence. For what can be several decades, the person may feel almost nothing beyond mild fatigue or subtle cognitive fog. Liver enzyme levels remain within normal range in 7 to 53% of chronically infected individuals. Fatty changes accumulate in roughly half of those affected, usually before scarring begins. Over thirty years, 10 to 30% progress to cirrhosis, and those who cross that threshold face a 20-fold elevated risk of liver cancer, developing at one to three percent per year.

How It Spreads – and What It Doesn't

Hepatitis C travels almost exclusively through blood. The principal routes include injection drug use with shared or inadequately sterilized equipment, needlestick injuries in clinical settings, and blood transfusions from unscreened donors. In regions where systematic blood screening has been adopted, the transfusion-related risk has fallen to fewer than one case per two million units. A smaller but real pathway exists from an infected mother to her child during delivery. What the virus does not do is spread through everyday life. Breast milk, food, water, hugging, kissing, and sharing drinks or utensils with an infected person all pose no risk. This distinction matters enormously for reducing stigma and fear in families and communities. Diagnosis relies on blood testing, either detecting antibodies directed against the virus or identifying viral RNA directly. In the United States, guidelines recommend that every adult between the ages of 18 and 79 undergo at least one HCV screen. Because no vaccine exists, prevention rests on harm-reduction programs for people who inject drugs, rigorous screening of the blood supply, and prompt treatment of those already carrying a chronic infection to cut the chain of transmission.

The Treatment Revolution – From Partial Cures to Near-Certain Eradication

For years, the standard against chronic hepatitis C was a combination of peginterferon and ribavirin. The regimen was grueling and its success rate hovered below 50%, with a heavy burden of side effects that often drove patients to abandon therapy. Everything shifted with the arrival of direct-acting antivirals such as sofosbuvir and simeprevir. These newer agents cure chronic infection in more than 95% of cases, a dramatic leap over the previous generation. For a time, however, the cost of these drugs placed them beyond the reach of many patients and health systems. By 2022, the introduction of generic versions had driven prices down sharply, particularly in low-income and lower-middle-income countries, widening access considerably. For the subset of patients who progress to cirrhosis or liver cancer before receiving antiviral therapy, a liver transplant may become necessary. Hepatitis C ranks among the leading indications for transplantation worldwide. Yet the virus typically reappears after the new liver is in place, underscoring why early treatment remains the most powerful intervention available.

A Global Footprint and a Reach Beyond the Liver

In 2019, an estimated 58 million people worldwide carried the hepatitis C virus, and roughly 290,000 deaths that year were attributed to it, the majority stemming from liver cancer and cirrhosis. The virus infects only humans and chimpanzees, a narrow host range that has shaped both its epidemiology and the difficulty of studying it in animal models. What was once called non-A, non-B hepatitis was first suspected in the 1970s, but the virus was not definitively identified until 1989. It stands as one of five recognized hepatitis viruses—A, B, C, D, and E. Beyond the liver, chronic HCV infection casts a long shadow. The most common extrahepatic manifestation is mixed cryoglobulinemia, an inflammation of small and medium blood vessels. The virus is also linked to autoimmune conditions including Sjögren's syndrome, lichen planus, and B-cell lymphoproliferative disorders. Insulin resistance and diabetes appear at elevated rates, and 20 to 30% of infected individuals carry rheumatoid factor. An increased risk of pancreatic cancer has also been reported, reminding clinicians that hepatitis C is a whole-body condition, not merely a liver problem.

Gallery